To include your compound in the COVID-19 Resource Center, submit it here.

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

With Sangamo’s zing finger technology, Biogen hopes to halt expression of neurodegeneration targets

In its latest CNS partnership, Biogen is doubling down on targets already in its pipeline with a gene regulation technology from Sangamo it hopes will shut down target expression altogether.

By closing off target expression, the company takes a different, possibly complementary, approach to treating Alzheimer’s disease (AD) and Parkinson’s disease, where the prevailing strategy is to block proteins from exerting their toxic effects.

Biogen Inc. (NASDAQ:BIIB) is stacking up on different modalities, with different risk profiles and probabilities of success, suggesting it

Read the full 811 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers